Shimon Slavin

Scientific & Medical Director
The International Center for Cell Therapy & Cancer Immunotherapy (CTCI)
E-mail: slavinMD@gmail.com
Page: http://www.CTCIcenter.com

Fields of interest: 

Cancer immunotherapy

Transplantation tolerance

Regenerative medicine

 

Recent publications:

Karussis D, Kassis I, Kurkalli BG, Slavin S.:
Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases
J Neurol Sci. 2008 Feb 15;265(1-2):131-5.

Prigozhina TB, Elkin G, Khitrin S, Slavin S.:
Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
Exp Hematol. 2008 Dec;36(12):1750-9.

Slavin S, Kurkalli BG, Karussis D.:
The potential use of adult stem cells for the treatment of multiple sclerosis and other neurodegenerative disorders.
Clin Neurol Neurosurg. 2008 Nov;110(9):943-6.

Karussis D, Kassis I, Kurkalli BG, Slavin S.:
Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and otherneuroimmunological/neurodegenerative diseases.
J Neurol Sci. 2008 Feb 15;265(1-2):131-5. 

Burt RK, Abinun M, Farge-Bancel D, Fassas A, Hiepe F, Havrdova, Ikehara S, Loh Y, Marmont A, Voltarelli JC, Snowden J, Slavin S.:
Risks of immune system treatments.
Science 2010, 328: 825-6.

Nagler A, Berger R, Ackerstein A, Czyz JA, Diez-Martin JL, Naparstek E, Or R, Gan S, Shimoni A, Slavin S.:
A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation.
J Immunother.2010 Apr;33(3):326-33.

Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, Bulte JW, Petrou P, Ben-Hur T, Abramsky O, Slavin S.:
Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.
Arch Neurol. 2010 Oct;67(10):1187-94.

Slavin S, Ackerstein A, Or R, Shapira MY, Gesundheit B, Askenasy N, Morecki S.:
Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study.
Cancer Immunol Immunother.2010 Oct;59(10):1511-9.